We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

131 hedge funds and large institutions have $827M invested in Intra-Cellular Therapies Inc. in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 47 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $49.9M | Put options by funds: $26.3M

19% more capital invested

Capital invested by funds: $692M → $827M (+$135M)

0% more funds holding

Funds holding: 131 → 131 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

15% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 47

Holders
131
Holders Change
–
Holders Change %
0%
% of All Funds
2.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
40
Reduced
47
Closed
11
Calls
$49.9M
Puts
$26.3M
Net Calls
+$23.7M
Net Calls Change
+$8.87M

Top Buyers

1
Franklin Resources
Franklin Resources
California
+$10.3M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.3M
3
CS
Candriam SCA
Luxembourg
+$6.5M
4
FCM
Farallon Capital Management
California
+$5.23M
5
BlackRock
BlackRock
New York
+$2.79M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$11.4M
2
Millennium Management
Millennium Management
New York
-$8.5M
3
PC
PointState Capital
New York
-$8.39M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.36M
5
Deutsche Bank
Deutsche Bank
Germany
-$7.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
126
Daiwa Securities Group
Japan
$7K – – –
DBT
127
Dubuque Bank & Trust
Iowa
$5K – – –
LF
128
Lee Financial
Texas
$4K -$3.14K -150 -43%
CWM
129
Catamount Wealth Management
Connecticut
$4K +$4.08K +195 New
LTFS
130
Ladenburg Thalmann Financial Services
Florida
$3K – – –
HMS
131
Hanseatic Management Services
New Mexico
$1K – – –
PC
132
PointState Capital
New York
– -$8.39M -475,000 Closed
GCP
133
GSA Capital Partners
United Kingdom
– -$859K -48,594 Closed
PVI
134
Pura Vida Investments
New York
– -$418K -20,000 Closed
TI
135
Trexquant Investment
Connecticut
– -$249K -14,096 Closed
QIM
136
Quantitative Investment Management
Virginia
– -$226K -12,800 Closed
DTL
137
Dynamic Technology Lab
Singapore
– -$213K -12,048 Closed
AIM
138
Assured Investment Management
New York
– -$144K -8,176 Closed
HIIFS
139
Harel Insurance Investments & Financial Services
Israel
– -$76K -4,300 Closed
PHK
140
Point72 Hong Kong
Hong Kong
– -$24K -1,335 Closed
PIA
141
Piedmont Investment Advisors
North Carolina
– -$14K -778 Closed
Federated Hermes
142
Federated Hermes
Pennsylvania
– -$1K -27 Closed
2 3 4 5
6

ITCI Hedge Fund Activity: Q3 2018 in Review

131 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2018, worth a combined $827M — up 19% from $692M a quarter earlier.

Fund positioning in ITCI was balanced in Q3 2018: 11 funds opened new positions, 11 closed out, 40 added to existing stakes and 47 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $10.3M. The largest seller was Citadel Advisors, cutting an estimated $11.4M.

  • 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $827M of Intra-Cellular Therapies Inc. stock for Q3 2018, up 19% quarter-over-quarter.
  • 11 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2018 and 11 closed out, a net change of 0 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2018 was Franklin Resources, an estimated $10.3M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2018 was Citadel Advisors, an estimated $11.4M sold.

Based on aggregated 13F filings for Q3 2018.